Joseph Patti
Director/Board Member bei ARMATA PHARMACEUTICALS, INC.
Vermögen: - $ am 31.03.2024
Aktive Positionen von Joseph Patti
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARMATA PHARMACEUTICALS, INC. | Director/Board Member | 09.05.2019 | - |
Independent Dir/Board Member | 09.05.2019 | - | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Director/Board Member | 01.03.2019 | - |
JP Biotech Advisors, Inc. | President | 01.02.2018 | - |
Karriereverlauf von Joseph Patti
Ehemalige bekannte Positionen von Joseph Patti
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01.06.2022 | 14.09.2023 |
Chief Executive Officer | 01.06.2022 | 14.09.2023 | |
President | 01.06.2022 | 14.09.2023 | |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Director/Board Member | 01.08.2019 | 01.07.2021 |
Chief Executive Officer | 01.08.2019 | 01.07.2021 | |
Chairman | 01.11.2018 | 01.08.2019 | |
President | 01.08.2019 | 01.07.2021 | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director/Board Member | 01.10.2014 | 01.02.2018 |
Chief Executive Officer | 01.10.2014 | 01.02.2018 | |
Corporate Officer/Principal | 12.11.2012 | 01.10.2014 | |
President | 01.10.2014 | 01.02.2018 | |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Director/Board Member | 01.01.2012 | 01.01.2015 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Director/Board Member | 01.01.1998 | 01.01.2005 |
Chief Tech/Sci/R&D Officer | 01.05.1994 | 01.02.2012 | |
Founder | 01.05.1994 | 01.02.2012 | |
Institute of Biosciences & Technology | Corporate Officer/Principal | 01.01.1994 | 01.01.1998 |
░░░░░ ░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ | - | - |
Ausbildung von Joseph Patti
University of Pittsburgh | Undergraduate Degree |
The University of Alabama at Birmingham | Doctorate Degree |
The University of Miami Leonard M. Miller School of Medicine | Graduate Degree |
Statistik
International
Vereinigte Staaten | 15 |
Operativ
Director/Board Member | 7 |
President | 5 |
Chief Executive Officer | 4 |
Sektoral
Health Technology | 7 |
Consumer Services | 6 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
VAXART, INC. | Health Technology |
ARMATA PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Health Technology |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Health Technology |
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Commercial Services |
JP Biotech Advisors, Inc. | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Technology Services |
- Börse
- Insiders
- Joseph Patti
- Erfahrung